US FDA warns Hims & Hers over misleading claims on diabetes, weight-loss drugs

Core Point - The U.S. Food and Drug Administration has issued a warning letter to telehealth firm Hims & Hers Health concerning its compounded versions of Novo Nordisk's diabetes drug Ozempic and weight-loss treatment Wegovy [1] Company Summary - Hims & Hers Health is facing regulatory scrutiny from the FDA for its compounded medications related to popular diabetes and weight-loss treatments [1] Industry Summary - The telehealth industry is experiencing increased regulatory oversight, particularly regarding the compounding of pharmaceuticals, which may impact operational practices and compliance requirements [1]